Regeneron (NASDAQ:REGN) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
A number of other brokerages have also recently commented on REGN. BMO Capital Markets lifted their target price on shares of Regeneron from $398.00 to $444.00 and gave the stock a “market perform” rating in a research report on Thursday, February 8th. Argus decreased their target price on shares of Regeneron from $540.00 to $470.00 and set a “buy” rating on the stock in a research report on Thursday, December 28th. Cowen reiterated a “hold” rating and issued a $450.00 target price on shares of Regeneron in a research report on Wednesday, February 7th. BTIG Research cut shares of Regeneron from a “buy” rating to a “neutral” rating and set a $480.00 target price on the stock. in a research report on Thursday, February 8th. Finally, Leerink Swann decreased their target price on shares of Regeneron from $568.00 to $502.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Four equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $448.72.
NASDAQ REGN opened at $322.63 on Wednesday. Regeneron has a 52-week low of $313.53 and a 52-week high of $543.55. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The firm has a market cap of $34,268.87, a PE ratio of 24.06, a P/E/G ratio of 1.03 and a beta of 1.46.
Regeneron (NASDAQ:REGN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. The firm’s revenue was up 28.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.04 EPS. equities analysts expect that Regeneron will post 19.2 EPS for the current year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the business’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $350.02, for a total transaction of $700,040.00. Following the transaction, the director now owns 14,000 shares in the company, valued at approximately $4,900,280. The disclosure for this sale can be found here. Insiders have sold 5,000 shares of company stock worth $1,705,640 in the last quarter. 10.80% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in REGN. Dimensional Fund Advisors LP increased its position in shares of Regeneron by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 161,491 shares of the biopharmaceutical company’s stock valued at $72,193,000 after buying an additional 633 shares during the period. Vident Investment Advisory LLC purchased a new position in shares of Regeneron during the third quarter valued at about $200,000. Atlantic Trust Group LLC purchased a new position in shares of Regeneron during the third quarter valued at about $3,560,000. DnB Asset Management AS purchased a new position in shares of Regeneron during the fourth quarter valued at about $9,136,000. Finally, Atria Investments LLC increased its position in shares of Regeneron by 50.4% during the fourth quarter. Atria Investments LLC now owns 1,930 shares of the biopharmaceutical company’s stock valued at $726,000 after buying an additional 647 shares during the period. Institutional investors own 66.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/18/bidaskclub-downgrades-regeneron-regn-to-sell.html.
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.